EA
COLL icon

Emerald Advisers’s Collegium Pharmaceutical COLL Stock Holding History

Emerald Advisers’s Portfolio COLL Stock Details COLL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$38K Sell
1,049
-401,703
-100% -$13.7M ﹤0.01% 230
2026
Q1 		$13.3M Sell
402,752
-226,592
-36% -$9.59M 0.42% 88
2025
Q4 		$29.1M Sell
629,344
-10,350
-2% -$433K 0.9% 45
2025
Q3 		$22.4M Sell
639,694
-197,855
-24% -$6.88M 0.72% 59
2025
Q2 		$24.8M Buy
837,549
+11,074
+1% +$316K 0.91% 38
2025
Q1 		$24.7M Buy
826,475
+14,795
+2% +$452K 1.11% 35
2024
Q4 		$23.3M Sell
811,680
-15,622
-2% -$517K 0.9% 43
2024
Q3 		$32M Buy
827,302
+177,129
+27% +$6.32M 1.24% 24
2024
Q2 		$20.9M Sell
650,173
-19,339
-3% -$671K 0.88% 46
2024
Q1 		$26M Buy
669,512
+3,416
+0.5% +$120K 1.05% 33
2023
Q4 		$20.5M Sell
666,096
-24,391
-4% -$611K 0.88% 45
2023
Q3 		$15.4M Sell
690,487
-114,303
-14% -$2.61M 0.75% 56
2023
Q2 		$17.3M Buy
804,790
+1,654
+0.2% +$37.6K 0.76% 62
2023
Q1 		$19.3M Sell
803,136
-10,553
-1% -$280K 0.92% 42
2022
Q4 		$18.9M Sell
813,689
-3,460
-0.4% -$69.8K 0.91% 48
2022
Q3 		$13.1M Buy
817,149
+4,671
+0.6% +$82.4K 0.68% 67
2022
Q2 		$14.4M Buy
812,478
+12,360
+2% +$208K 0.74% 55
2022
Q1 		$16.3M Buy
800,118
+225,281
+39% +$4.26M 0.62% 67
2021
Q4 		$10.7M Sell
574,837
-15,419
-3% -$301K 0.4% 92
2021
Q3 		$11.7M Sell
590,256
-151,022
-20% -$3.27M 0.42% 90
2021
Q2 		$17.5M Sell
741,278
-7,660
-1% -$177K 0.64% 71
2021
Q1 		$17.8M Sell
748,938
-86,704
-10% -$2.06M 0.64% 76
2020
Q4 		$16.7M Buy
835,642
+122,279
+17% +$2.39M 0.56% 82
2020
Q3 		$14.9M Buy
713,363
+135,050
+23% +$2.44M 0.61% 68
2020
Q2 		$10.1M Sell
578,313
-187,517
-24% -$3.67M 0.44% 85
2020
Q1 		$12.5M Sell
765,830
-14,990
-2% -$309K 0.72% 51
2019
Q4 		$16.1M Buy
+780,820
New +$13M 0.68% 58

Other funds holding COLL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Emerald Advisers's COLL Position: Q2 2026 in Review

Emerald Advisers reduced its Collegium Pharmaceutical (COLL) stake by 100% in Q2 2026, selling an estimated $13.7M and leaving 1,049 shares worth $38K. The position accounts for ﹤0.01% of the portfolio, ranked #230.

Emerald Advisers first reported a position in COLL in Q4 2019 and has held it in 27 quarters since. The position peaked at $32M in Q3 2024. 279 funds tracked by Wall St. Rank hold COLL as of Q2 2026.

  • Emerald Advisers held 1,049 shares of Collegium Pharmaceutical worth $38K as of Q2 2026.
  • Emerald Advisers sold 401,703 Collegium Pharmaceutical shares in Q2 2026, an estimated $13.7M.
  • Collegium Pharmaceutical made up ﹤0.01% of Emerald Advisers's portfolio in Q2 2026, its #230 holding.
  • Emerald Advisers first reported a position in Collegium Pharmaceutical in Q4 2019 and has held it in 27 quarters since.
  • Emerald Advisers's Collegium Pharmaceutical position peaked at $32M in Q3 2024.
  • 279 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q2 2026.

Based on Emerald Advisers's 13F filing for Q2 2026, filed 5 Aug 2026.